Results 261 to 270 of about 34,959 (356)

Prescribing direct-acting antivirals for hepatitis C treatment: a scoping review of factors that influence primary care providers. [PDF]

BMC Prim Care
Hallett J, Price T, Gray C, Rosenberg S, Lobo R, Crawford G.   +5 more
europepmc   +1 more source

Hepatitis C Virus in Children: Deferring Treatment in Expectation of Direct-Acting Antiviral Agents.

, 2015
Esther Granot, Étienne Sokal
openalex   +1 more source

Safety, Pharmacokinetics, and Dose Recommendations for Nirmatrelvir/Ritonavir in Individuals with Mild to Moderate COVID‐19 and Severe Renal Impairment

Clinical Pharmacology &Therapeutics, EarlyView.
Patients with severe renal impairment and COVID‐19 are at high risk for severe disease and death. Nirmatrelvir/ritonavir, an antiviral therapy for COVID‐19, is eliminated by renal excretion and can accumulate in patients with severe renal impairment.
Jacqueline Gerhart, Candace R. Bramson, Michelle Goulding, Haihong Shi, Olayide Oladoyinbo, Phylinda L. S. Chan, Sunring Chime, Jennifer Hammond   +7 more
wiley   +1 more source

Modulation of glucose metabolism and insulin resistance following hepatitis C virus clearance via direct-acting antivirals. [PDF]

Sci Rep
Jabeen S, Khan R, Alrashed MM, Ullah S, Nabi G, Ullah MI, Waqar AB, Attia KA, Kimiko I.   +8 more
europepmc   +1 more source

Direct-Acting Antiviral Initiation Among People With Hepatitis C Virus (HCV) and HIV on Antiretroviral Therapy in the United States and Canada: Factors Driving the HCV Treatment Gap [PDF]

Raynell Lang, Elizabeth Humes, Asya Lyass, Leila H. Borowsky, Brenna Hogan, Arthur Y. Kim, Michael P. LaValley, Michael J. Silverberg, H. Nina Kim, Sonia Napravnik, Richard D. Moore, Michael A. Horberg, Frank J. Palella, Greg Kirk, Edward R. Cachay, George A. Yendewa, Seble Kassaye, Kathleen A. McGinnis, Sally B. Coburn, Timothy R. Sterling, Marina B. Klein, Mari M. Kitahata, Catherine R. Lesko, Virginia A. Triant, Keri N. Althoff   +24 more
openalex   +1 more source

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study

Clinical Pharmacology &Therapeutics, EarlyView.
AGILE (NCT04746183) is a Phase Ib/IIa platform, evaluating candidates to treat COVID‐19. Candidate Specific Trial 6 evaluated the safety and optimal dose of a novel intravenous formulation of favipiravir in a dose‐escalating, open‐label, randomized, controlled, Bayesian adaptive Phase Ib trial.
Tim Rowland, Richard FitzGerald, Elizabeth Challenger, Laura Dickinson, Laura J. Else, Lauren Walker, Colin Hale, Victoria Shaw, Callum Kelly, Rebecca Lyon, Jennifer Gibney, Karim Dhamani, Margaret Irwin, Yvanne Enever, Michelle Tetlow, William Wood, Helen Reynolds, Justin Chiong, Orod Osanlou, Henry Pertinez, Katie Bullock, William Greenhalf, Andrew Owen, David G. Lalloo, Michael Jacobs, Julian A. Hiscox, Thomas Jaki, Pavel Mozgunov, Geoffrey Saunders, Gareth Griffiths, Saye H. Khoo, Thomas E. Fletcher, on behalf of the AGILE CST‐6 Study Group, Shazaad Ahmad, Christopher J. Edwards, Lesley Dry, Georgie McKenzie, Aleksandra Ros, Michael Stackpoole, Laura Bradley, Karen Jennings‐Wilding, Nicholas Paton, Fred Hayden, Janet Darbyshire, Amy Lucas, Ulrika Lorch, Andrew Freedman, Richard Knight, Steven Julious   +48 more
wiley   +1 more source

Retraction: Outcomes of Direct-Acting Antivirals Versus Interferon-Based Therapy in Chronic Hepatitis C Infection. [PDF]

Cureus
Chowdhury R, Rashid W, Singh T, Rehman A, Daterdiwala NF, Mkosi V, Limbu B, Bukhari SA, Ramadhan A, Dabas MM, Shehryar A, Khan R.   +11 more
europepmc   +1 more source

Learning Strategies from Nature's Blueprint to Cyclic Carbonate Synthesis

ChemSusChem, Volume 18, Issue 6, March 15, 2025.
The development of sustainable synthetic methods for cyclic carbonates draws inspiration from nature, focusing on eco‐friendly processes and renewable resources like CO2 and biomass. This review explore various CO2 activation mechanisms, green chemistry principles, and green catalysts.
Erika Saccullo, Vincenzo Patamia, Chiara Zagni, Antonio Rescifina, Giuseppe Floresta   +4 more
wiley   +1 more source

The Role of Direct-Acting Antivirals in Enhancing Quality of Life Among Individuals with Chronic Hepatitis C. [PDF]

Healthcare (Basel)
Pirlog MC, Danilescu CM, Alexandru DO, Streba CT, Rogoveanu I.   +4 more
europepmc   +1 more source